Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2,D-Pen5]-enkephalin (DPDPE): Pharmacokinetic consequences of the interplay between multiple transport systems

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 3, 2004, Pages 1203-1210

  Hoffmaster, Keith A ^a   Zamek Gliszczynski, Maciej J ^a   Pollack, Gary M ^a   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELACRIDAR; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG TRANSPORT; HEPATOBILIARY SYSTEM; LIVER CELL MEMBRANE; LIVER PERFUSION; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSPORT KINETICS;

ACRIDINES; ANIMALS; AREA UNDER CURVE; BILE; CARRIER PROTEINS; ENKEPHALIN, D-PENICILLAMINE (2,5)-; HEPATOCYTES; LIVER; MALE; MITOCHONDRIAL PROTEINS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RATS; RATS, WISTAR; RIBOSOMAL PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; TETRAHYDROISOQUINOLINES;

EID: 10044241598     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.070201     Document Type: Article

References (36)

1. Allen JD, Brinkhuis RF, Wijnholds J, and Schinkel AH (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241.
2. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, and Schinkel AH (2003) Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63:1339-1344.
3. Bakos E, Evers R, Sinko E, Varadi A, Borst P, and Sarkadi B (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57:760-768.
4. Booth CL, Brouwer KR, and Brouwer KLR (1998) Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res 58:3641-3648.
5. Brouwer KLR and Thurman RG (1996) Isolated perfused liver. Pharm Biotechnol 8:161-192.
6. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T, and Keppler D (1996) cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271:15091-15098.
7. Chen C and Pollack GM (1996) Development of a capillary zone electrophoresis assay to examine the disposition of [D-pen2,5]enkephalin in rats. J Chromatogr B Biomed Appl 681:363-373.
8. Chen C and Pollack GM (1997) Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats. Pharm Res (NY) 14:345-350.
9. Chen C and Pollack GM (1998) Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 287:545-552.
10. Chen C and Pollack GM (1999) Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm Res (NY) 16:296-301.
11. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
12. Dresser GK, Schwarz UI, Wilkinson GR, and Kim RB (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 73:41-50.
13. 2,5] enkephalin. Drug Metab Dispos, in press.
14. Horio M, Chin KV, Currier SJ, Goldenberg S, Williams C, Pastan I, Gottesman MM, and Handler J (1989) Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 264:14880-14884.
15. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
16. - rats. AAPS PharmSci 5:W4365.
17. Keppler D, Konig J, and Buchler M (1997) The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv Enzyme Regul 37:321-333.
18. Kouzuki H, Suzuki H, Stieger B, Meier PJ, and Sugiyama Y (2000) Characterization of the transport properties of organic anion transporting polypeptide 1 (oatp1) and Na(+)/taurocholate cotransporting polypeptide (Ntcp): comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. J Pharmacol Exp Ther 292:505-511.
19. Morikawa A, Goto Y, Suzuki H, Hirohashi T, and Sugiyama Y (2000) Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2. Pharm Res (NY) 17:546-552.
20. Sasaki M, Suzuki H, Ito K, Abe T, and Sugiyama Y (2002) Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 277:6497-6503.
21. Sathirakul K, Suzuki H, Yamada T, Hanano M, and Sugiyama Y (1994) Multiple transport systems for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 268:65-73.
22. Seglen PO (1973) Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. Exp Cell Res 82:391-398.
23. Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29-83.
24. Shin HC, Kato Y, Yamada T, Niinuma K, Hisaka A, and Sugiyama Y (1997) Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. Am J Physiol 272:G979-G986.
25. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, and Sugiyama Y (2001) Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther 298:316-322.
26. Tang F and Borchardt RT (2002a) Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE. Pharm Res (NY) 19:780-786.
27. Tang F and Borchardt RT (2002b) Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm Res (NY) 19:787-793.
28. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
29. Tsuji A, Yoshikawa T, Nishide K, Minami H, Kimura M, Nakashima E, Terasaki T, Miyamoto E, Nightingale CH, and Yamana T (1983) Physiologically based pharmacokinetic model for beta-lactam antibiotics I: tissue distribution and elimination in rats. J Pharm Sci 72:1239-1252.
30. Ueda K, Kato Y, Komatsu K, and Sugiyama Y (2001) Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther 297:1036-1043.
31. Vore M, Hoffman T, and Gosland M (1996) ATP-dependent transport of beta-estradiol 17-(beta-D-glucuronide) in rat canalicular membrane vesicles. Am J Physiol 271:G791-G798.
32. Wu CY and Benet LZ (2003) Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine and gg918. Drug Metab Dispos 31:1292-1295.
33. Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, and Brouwer KLR (2002) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30:962-969.
34. Yamada T, Kato Y, Kusuhara H, Lemaire M, and Sugiyama Y (1998) Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein. Biol Pharm Bull 21:874-878.
35. Yamazaki M, Suzuki H, and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res (NY) 13:497-513.
36. Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, and Brouwer KLR (2003) Pharmacokinetics of 5 (and 6)-carboxy-2′,7′- dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther 304:801-809.